Recognizing heart disease. Helping women seek treatment faster.

C. Arslanian-Engoren

AWHONN Lifelines

Abstract:

What problem does this paper attempt to address?

Frequency and causes of premature extractions of deciduous molar teeth – a retrospective study

Angelika Kobylińska,Joanna Borawska,A. Chojnowska,Joanna Janczewska,Anna Turska-Szybka,D. Olczak-Kowalczyk

DOI: https://doi.org/10.5604/14266911.1154071

2015-03-04

Abstract:Summary Introduction. Premature loss of deciduous molar teeth is a common cause of dysfunction of the masticatory system. Analysis of the causes of premature extractions of these teeth will allow the appropriate targeting of preventive and therapeutic interventions. Aim. To determine the frequency and causes of premature extraction of deciduous molar teeth. Material and methods. Analysis of randomly selected 1880 medical records of the patients of the Department of Pediatric Dentistry (Medical University of Warsaw) concerned the necessity and causes of premature extractions of deciduous molar teeth in children under the age of 6 and the course of previous dental treatment. Data was analyzed statistically using the Mann-Whitney U-test, Spearman's rank correlation and a chi-square test; significance level - p ≤ 0.05. Results. 228 deciduous molar teeth were extracted in 139 children, most commonly due to inflammation of the pulp and its complications (abscesses, fistulas) - 84.7%, and carious destruction - 7.9%. The incidence of acute purulent inflammation decreased with age, whereas the occurrence of chronic pulpitis increased. 87.3% of the extracted teeth had not been previously treated, 7.5% had fillings and 5.2% had been pulpotomized. 54.7% of the patients had a single tooth removed and the rest - more than one. Maxillary first molars were most frequently extracted. There was no statistically significant difference in terms of gender. No relationship between age and the number of the removed tooth was found. There was a positive correlation between chronic inflammation of the pulp and age; negative correlation was found between age and acute inflammatory process of the pulp or periapical tissue as causes of extraction (Spearman's rank correlation, p < 0.05). A statistically significant difference in the average amount of premature extractions performed per one patient was found - more than one tooth was more often extracted in boys (Mann-Whitney U-test, P = 0.034).
Developing an Evaluation Plan for Nationwide Data Infrastructure Programs

S. West,Jacqueline B Amoozegar,M. Ashok,J. Richardson,B. Blumenfeld,Susan Lumsden,C. Cravens

Abstract:
Macrophage membrane-camouflaged biomimetic nanoparticles for rheumatoid arthritis treatment via modulating macrophage polarization

Renpeng Zhou,Song Xue,Yuanzhi Cheng,Yong Chen,Yan Wang,Jing Xing,Hao Liu,Yucai Xu,Yi Lin,Zejun Pei,Xin Wei,Jie Ding,Shufang Li,Ke Wang,Feng Yao,Yingjie Zhao,Changhai Ding,Wei Hu

DOI: https://doi.org/10.1186/s12951-024-02822-9

2024-09-19

Abstract:Rheumatoid arthritis (RA) is a debilitating autoimmune disease characterized by chronic joint inflammation and cartilage damage. Current therapeutic strategies often result in side effects, necessitating the development of targeted and safer treatment options. This study introduces a novel nanotherapeutic system, 2-APB@DGP-MM, which utilizes macrophage membrane (MM)-encapsulated nanoparticles (NPs) for the targeted delivery of 2-Aminoethyl diphenylborinate (2-APB) to inflamed joints more effectively. The NPs are designed with a matrix metalloproteinase (MMP)-cleavable peptide, allowing for MMP-responsive drug release within RA microenvironment. Comprehensive in vitro and in vivo assays confirmed the successful synthesis and loading of 2-APB into the DSPE-GPLGVRGC-PEG (DGP) NPs, as well as their ability to repolarize macrophages from a pro-inflammatory M1 to an anti-inflammatory M2 phenotype. The NPs demonstrated high biocompatibility, low cytotoxicity, and enhanced cellular uptake. In a collagen-induced arthritis (CIA) mouse model, intra-articular injection of 2-APB@DGP-MM significantly reduced synovial inflammation and cartilage destruction. Histological analysis corroborated these findings, demonstrating marked improvements in joint structure and delayed disease progression. Above all, the 2-APB@DGP-MM nanotherapeutic system offers a promising and safe approach for RA treatment by modulating macrophage polarization and delivering effective agents to inflamed joints.
Efficient Treatment of Rheumatoid Arthritis by Degradable LPCE Nano-Conjugate-Delivered p65 siRNA

Xiaohua Chen,Bailing Zhou,Yan Gao,Kaiyu Wang,Jieping Wu,Ming Shuai,Ke Men,Xingmei Duan

DOI: https://doi.org/10.3390/pharmaceutics14010162

IF: 6.525

2022-01-11

Pharmaceutics

Abstract:Rheumatoid arthritis (RA) is one of the most common autoimmune diseases worldwide, causing severe cartilage damage and disability. Despite the recent progress made in RA treatment, limitations remain in achieving early and efficient therapeutic intervention. Advanced therapeutic strategies are in high demand, and siRNA-based therapeutic technology with a gene-silencing ability represents a new approach for RA treatment. In this study, we created a cationic delivery micelle consisting of low-molecular-weight (LMW) polyethylenimine (PEI)–cholesterol–polyethylene glycol (PEG) (LPCE) for small interfering RNA (siRNA)-based RA gene therapy. The carrier is based on LMW PEI and modified with cholesterol and PEG. With these two modifications, the LPCE micelle becomes multifunctional, and it efficiently delivered siRNA to macrophages with a high efficiency greater than 70%. The synthesized LPCE exhibits strong siRNA protection ability and high safety. By delivering nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) p65 siRNA, the p65 siRNA/LPCE complex efficiently inhibited macrophage-based cytokine release in vitro. Local administration of the p65 siRNA/LPCE complex exhibited a fast and potent anti-inflammatory effect against RA in a mouse model. According to the results of this study, the functionalized LPCE micelle that we prepared has potential gene therapeutic implications for RA.

pharmacology & pharmacy
Biomimetic chitosan nanoparticles with simultaneous water lubricant and anti-inflammatory

Lumin Yang,Haofei Huang,Huajing Zeng,Xiaoduo Zhao,Rui Wang,Zhengfeng Ma,Zengjie Fan,Shuanhong Ma,Feng Zhou,Yong-min Liang

DOI: https://doi.org/10.1016/j.carbpol.2022.120503

IF: 10.723

2022-12-31

Carbohydrate Polymers

Abstract:Rheumatoid arthritis (RA) is a chronic inflammatory immune and lubrication dysfunction disease that causes great damage to the joints. Herein, inspired by the unique biochemistry structure and excellent hydration of chondroitin sulfate (CHI) existing in joint system, one kind of novel polysaccharide nanoparticle lubricant, that is chitosan nanoparticles (CS NPs) grafting CHI (CS-CHI), is synthesized by one-step surface chemistry reaction. CHI with negative charges can form hydration layers on the surface of CS NPs, thus improving the lubricity of nanoparticles. Simultaneously, CS-CHI NPs have effective loading and sustained drug release ability for anti-inflammatory drug diclofenac sodium (DS), along with good biocompatibility. Finally, based on a collagen-induced rat RA model, in vitro animals experimental results indicate that the as-synthesized NPs has obvious inhibitory effects on inflammatory factors and can effectively prevent the damaged cartilage from further destruction.

polymer science,chemistry, organic, applied
Targeted co-delivery biomimetic nanoparticles reverse macrophage polarization for enhanced rheumatoid arthritis therapy

Xiu Zheng,Xin Yu,Chenglong Wang,Yan Liu,Ming Jia,Fenting Lei,Ji Tian,Chunhong Li

DOI: https://doi.org/10.1080/10717544.2022.2057616

IF: 6.819

2022-04-01

Drug Delivery

Abstract:Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease, which is characterized by synovial inflammation and autoimmunity. The main cause of the disease is the imbalance of the proportion of pro-inflammatory macrophages (M1-type) and anti-inflammatory macrophages (M2-type) in the synovial tissues of the joint. To restore this balance, in our study, the interleukin-10 encoding anti-inflammatory cytokines (IL-10 pDNA) and chemotherapeutic drug dexamethasone sodium phosphate (DSP) were co-loaded into human serum albumin (HSA) preparing pDNA/DSP-NPs to actively target macrophages in synovium tissue to promote M1-M2 polarization. Confocal laser scanning microscope and western blot were used to demonstrate the targeting ability of co-delivery nanoparticles. In vivo, the real-time fluorescence imaging system and HPLC were used to study the tissue distribution and pharmacokinetics of nanoparticles, and the results showed that the accumulation of nanoparticles in the inflammatory joint site was higher. Its pharmacodynamics were evaluated in collagen-induced arthritis (CIA) rat model, and it demonstrated that the pDNA/DSP-NPs significantly reduced the expression of serum inflammatory factors and alleviated joint swelling and bone erosion, suggesting the favorable therapeutic effect. The synergistic treatment effect of IL-10 pDNA and DSP in this system was achieved by reducing the secretion of pro-inflammatory factors (TNF-α, IL-1β) and increasing the expression of anti-inflammatory factors (IL-10) to promote the M1-M2 polarization of macrophages. Our strategy is promising for co-delivery of gene drugs and chemical drugs by biomimetic natural materials to promote macrophages polarization so that to achieve synergically treatment of inflammatory disease.

pharmacology & pharmacy
Nanoparticle-delivered siRNA targeting Bruton's tyrosine kinase for rheumatoid arthritis therapy

Gui Zhao,An Liu,Yue Zhang,Zu-Qi Zuo,Zhi-Ting Cao,Hou-Bing Zhang,Cong-Fei Xu,Jun Wang

DOI: https://doi.org/10.1039/c9bm01025d

2019-11-01

Abstract:Rheumatoid arthritis (RA) is a systemic autoimmune disease that can cause irreversible joint deformity. There is still no cure for RA, and current therapeutics, including methotrexate and adalimumab, cause serious off-target effects and systemic immunosuppression, which in turn increases the risk of infection. Bruton's tyrosine kinase (BTK) in macrophages and B cells has been demonstrated to be a promising therapeutic target for RA. However, high doses of BTK inhibitors are required for efficient BTK suppression, which limits their clinical use. Small interfering RNA (siRNA) is promising for the silencing of specific genes and has been used for the treatment of multiple diseases. To deliver siRNA into macrophages and B cells for BTK gene silencing, we employed cationic lipid-assisted PEG-b-PLGA nanoparticles (CLANs) to encapsulate siRNA. We demonstrated that macrophages and B cells were able to efficiently ingest the CLANs both in vitro and in vivo. Thereafter, we encapsulated siRNA targeting BTK (siBTK) into the CLANs, denoted as CLANsiBTK, and demonstrated that CLANsiBTK significantly inhibited BTK expression in macrophages and B cells. In a collagen-induced mouse arthritis model, CLANsiBTK treatment dramatically reduced joint inflammation and other RA symptoms but showed no toxicity, proving that using CLANsiBTK is a promising approach for RA therapy.
Radicals Scavenging MOFs Enabling Targeting Delivery of siRNA for Rheumatoid Arthritis Therapy

Lina Guo,Shenghui Zhong,Peng Liu,Man Guo,Jinsong Ding,Wenhu Zhou

DOI: https://doi.org/10.1002/smll.202202604

IF: 13.3

2022-06-05

Small

Abstract:An active targeting nanomedicine based on metal‐organic frameworks is synthesized through coordination between tannic acid and Fe3+, loaded with anti‐TNF‐α siRNA and then modified with bovine serum albumin. The nanosystem can selectively accumulate in inflamed joints, be selectively delivered into M1 macrophages, and exert anti‐RA efficacy through the synergistic effects between MOF vector and anti‐TNF‐α siRNA. Macrophages play essential roles in the progression of rheumatoid arthritis (RA), which are polarized into the pro‐inflammatory M1 phenotype with significant oxidative stress and cytokines excretion. Herein, an active targeting nanomedicine based on metal‐organic frameworks (MOFs) to re‐educate the diseased macrophages for RA therapy is reported. The MOFs are prepared via coordination between tannic acid (TA) and Fe3+, and anti‐TNF‐α siRNA is loaded via a simple sonication process, achieving high loading capacity comparable to cationic vectors. The MOFs show excellent biocompatibility, and enable rapid endo/lysosome escape of siRNA via the proton‐sponge effect for effective cytokines down‐regulation. Importantly, such nanomedicine displays intrinsic radicals scavenging capability to eliminate a broad spectrum of reactive oxygen and nitrogen species (RONS), which in turn repolarizes the M1 macrophages into anti‐inflammatory M2 phenotypes for enhanced RA therapy in combination with siRNA. The MOFs are further modified with bovine serum albumin (BSA) to allow cascade RA joint and diseased macrophages targeted delivery. As a result, an excellent anti‐RA efficacy is achieved in a collagen‐induced arthritis mice model. This work provides a robust gene vector with great translational potential, and offers a vivid example of rationally designing MOF structure with multifunctionalities to synergize with its payload for enhanced disease treatment.

materials science, multidisciplinary,chemistry, physical,physics, applied, condensed matter,nanoscience & nanotechnology
CaP-based anti-inflammatory HIF-1α siRNA-encapsulating nanoparticle for rheumatoid arthritis therapy

Xuesong Liu,Ruru Guo,Shicheng Huo,Huan Chen,Qingxiang Song,Gan Jiang,Ye Yu,Jialin Huang,Shaowei Xie,Xiaoling Gao,Liangjing Lu

DOI: https://doi.org/10.1016/j.jconrel.2022.01.029

IF: 11.467

2022-03-01

Journal of Controlled Release

Abstract:Rheumatoid arthritis (RA) is a common inflammatory disease and its treatment is largely limited by drug ineffectiveness or severe side effects. In RA progression, multiple signalling pathways, such as hypoxia-inducible factor (HIF)-1α, nuclear factor kappa B (NF-κB), and mitogen-activated protein kinase (MAPK) pathways, act synergistically to maintain the inflammatory response. To downregulate HIF-1α, NF-κB, and MAPK expression, we proposed HIF-1α siRNA-loaded calcium phosphate nanoparticles encapsulated in apolipoprotein E3-reconstituted high-density lipoprotein (HIF-CaP-rHDL) for RA therapy. Here, we evaluated the potential of CaP-rHDL nanoparticles in RA therapy using a murine macrophage line (RAW 264.7) and a collagen-induced arthritis (CIA) mouse model. The CaP-rHDL nanoparticles showed significant anti-inflammatory effects along with HIF-1α knockdown and NF-κB and MAPK signalling pathway inhibition in lipopolysaccharide-activated macrophages. Moreover, they inhibited receptor activator of NF-κB ligand (RANKL)-induced osteoclast formation. In CIA mice, their intravenous administration resulted in high accumulation at the arthritic joint sites, and HIF-CaP-rHDL effectively suppressed inflammatory cytokine secretion and relieved bone erosion, cartilage damage, and osteoclastogenesis. Thus, HIF-CaP-rHDL demonstrated great potential in RA precision therapy by inhibiting multiple inflammatory signalling pathways.

pharmacology & pharmacy,chemistry, multidisciplinary
Biomimetic Hybrid Membrane-Coated Xuetongsu Assisted with Laser Irradiation for Efficient Rheumatoid Arthritis Therapy

Huanghe Yu,Jialong Fan,Nuzhat Shehla,Yixing Qiu,Ye Lin,Zhou Wang,Liang Cao,Bin Li,Muhammad Daniyal,Yan Qin,Caiyun Peng,Xiong Cai,Bin Liu,Wei Wang

DOI: https://doi.org/10.1021/acsnano.1c07556

IF: 17.1

2021-12-29

ACS Nano

Abstract:Rheumatoid arthritis (RA) is a systemic autoimmune disease underlying a cascade of chronic inflammatory processes. Over the past decades, the response rate of effective RA treatments has remained scarce despite numerous advancements in the current therapeutic interventions, owing largely to the associated off-target adverse events and poor accumulation in the inflamed joints. Recently, there is a high interest in the development of targeted drug delivery system by using nanotechnology, as it can provide a handle to improve the therapy efficacy of RA. Here, multifunctional HA@RFM@PB@SE nanoparticles (HRPS NPs) are developed by loading schisanlactone E (SE, also called with xuetongsu), an anti-RA compound isolated from Tujia ethnomedicine xuetong, into Prussian blue nanoparticles (PB NPs) and further camouflage of RBC-RAFLS hybrid membrane with HA modification onto PB@SE NPs (PS NPs). We demonstrated that the modification of RFM makes PB NPs ideal decoys for targeting inflammatory mediators of arthritis due to the homing effects of the parental cells. Moreover, the encapsulation of RFM on the PB@SE NPs extended the blood circulation time and improved its targeting ability, which accordingly achieved optimal accumulation of SE in arthritic rat paws. In vitro and in vivo assay demonstrated the outstanding performance of HRPS NPs for synergistic chemo-/photothermal therapy of RA without side effects to healthy tissues. Molecular mechanism exploration indicated that the ultrastrong inhibition of synovial hyperplasia and bone destruction was partly via suppressing NF-κB signaling pathway and the expression of matrix metalloproteinases. In summary, the nanodrug delivery system showed controllable release behavior, targeted accumulation at arthritic sites and systemic regulation of immunity, hence improved therapeutic efficacy and clinical outcomes of the disease without attenuating safety.

materials science, multidisciplinary,chemistry, physical,nanoscience & nanotechnology
[Primacy of immunologic derangement over the immunopathologic changes and hemodynamic disorders in Hansenian neuritis].

A. Carayon

Abstract:
Notch-1 siRNA and Methotrexate towards a Multifunctional Approach in Rhematoid Arthritis Management: a Nanomedicine Approach

Guang Zhao,Haifei Zhang

DOI: https://doi.org/10.1007/s11095-018-2401-x

2018-04-20

Abstract:Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease and Notch pathway plays a pivotal role in synoviocytes involved in progression of RA. Methods: Herein, we have designed a self-assembled polymeric micelles based on polycaprolactone-polyethylene glycol (PCL-PEG) and polyethylenimine-polyethylene glycol (PEI-PEG) was prepared and loaded with methotrexate and Notch-1 siRNA for the effective treatment of rheumatoid arthritis. Results: The MTX/siRNA-loaded polymeric micelles (siM-PM) showed appreciable cellular uptake in Raw264.7 cells which were activated with LPS and did not exhibit any toxicity to Raw264.7 and HUVEC cells. The AUC of siM-PM was 4-fold higher compared to that of free MTX while t1/2 was 6 fold for siM-PM compared to that of free drug indicating the superior pharmacokinetic parameters. Importantly, siM-PM significantly reduced the paw thickness and slowed the disease progression remarkably, indicating that siM-PM is very effective in recovering the edema in arthritic animals. Importantly, 2-fold decrease in arthritic score was observed in siM-PM treated group at the end of day 24. The data clearly reveals anti-inflammatory effect of combinational nanoparticle due to the sequence specific downregulation of Notch-1 expression in the RA clinical models. Conclusions: Overall, nanomedicine-based delivery of MTX and siRNA could overcome the side effects of small molecules and could improve the therapeutic effect of siRNA in rheumatoid arthritis.
Biomimetic nanoparticles with cell-membrane camouflage for rheumatoid arthritis

Jingjing Gan,Danqing Huang,Junyi Che,Yuanjin Zhao,Lingyun Sun

DOI: https://doi.org/10.1016/j.matt.2023.12.022

IF: 18.9

2024-01-16

Matter

Abstract:Rheumatoid arthritis (RA) is a progressive, autoimmune disease that causes substantial suffering and high disability. Despite advances in the application potential of nano-drug-delivery platforms, rapid blood clearance and untargeted accumulation severely hinder their therapeutic efficacy in treating RA. More recently, cytomembrane wrapping has emerged as a promising solution addressing these limitations. Due to the abundant biocompatible proteins on their surface, cell-membrane-camouflaged nanoparticles (CMCNs) can effectively escape the immune system and realize highly targeted aggregation.

materials science, multidisciplinary
A novel indomethacin/methotrexate/MMP-9 siRNA in situ hydrogel with dual effects of anti-inflammatory activity and reversal of cartilage disruption for the synergistic treatment of rheumatoid arthritis

Na Yin,Xinyi Tan,Hongbing Liu,Fengming He,Ning Ding,Jingxin Gou,Tian Yin,Haibing He,Yu Zhang,Xing Tang

DOI: https://doi.org/10.1039/d0nr00454e

IF: 6.7

2020-04-21

Nanoscale

Abstract:Rheumatoid arthritis (RA) is an autoimmune disease characterized by inflammatory cell infiltration, and cartilage and bone disruption, which ultimately leads to loss of joint function. Current treatments for RA only focus on anti-inflammatory activity but neglect to prevent further damage to articular cartilage and bone. Here we attempted to co-deliver indomethacin (IND), methotrexate (MTX) and a small-interfering RNA targeting MMP-9 using an in situ hydrogel loaded with PEI-SS-IND-MTX-MMP-9 siRNA nanoparticles (D/siRNA-NGel) to treat RA synergistically and comprehensively. IND, MTX and MMP-9 siRNA were able to escape from the endosome and down-regulate the expression of MMP-9 and inflammatory cytokines of Raw-264.7 cells. After intra-articular injection in arthritic mice, the D/siRNA-NGel effectively relieved joint swelling and significantly reduced the expression of TNF-α, IL-6 and MMP-9 in the ankle fluid, knee joint fluid and plasma of RA mice without causing any side effects. Most importantly, the co-delivery system restored the morphological parameters of the ankle joints close to normal. The D/siRNA-NGel could achieve good anti-inflammatory activity and reverse cartilage disruption through a synergistic effect between chemical drugs and MMP-9 siRNA. This co-delivery system should have promising applications in the treatment of rheumatoid arthritis and other metabolic bone diseases which cause serious bone erosion.
DEMONSTRATION OF SEPARATE RECEPTORS FOR HUMAN IgA AND IgG IN GROUP A STREPTOCOCCI TYPE

C. Schalén,P. Christensen,A. Grubb,G. Samuelsson,M. Svensson

DOI: https://doi.org/10.1111/j.1699-0463.1980.tb00076.x

1980-11-01

Abstract:The alkaline extract of group A streptococci type 4 was separated by electrophoresis and diffused against 27 normal human sera. One of the precipitates appeared with 85% of the sera. Addition of purified IgA myeloma protein or sera containing IgA M‐components to the extract changed the electrophoretic mobility of the precipitate anodically. Purified IgG Fc‐fragments or sera containing IgG M‐component did not affect the mobility of the precipitate. It was concluded that this precipitate contained the streptococcal receptor for human IgA. A non‐precipitating IgG Fc‐receptor, with agglutinating capacity for cells coated with human IgG1 but not IgG3, was localized by preparative electrophoresis to the same electrophoretic region as the IgA receptor. The mobility of the IgG receptor remained unaltered on addition of IgA myeloma protein permitting a separation of the two receptors by preparative electrophoresis. The receptors were distinct from the group specific carbohydrate, peptidoglycan and lipoteichoic acid. No M antigen or opacity factor were demonstrated in the extract.
Delivery of siRNA using folate receptor-targeted pH-sensitive polymeric nanoparticles for rheumatoid arthritis therapy

Xiangshi Sun,Shiyan Dong,Xiangyu Li,Kongtong Yu,Fengying Sun,Robert J Lee,Youxin Li,Lesheng Teng

DOI: https://doi.org/10.1016/j.nano.2019.102017

Nanomedicine

Abstract:Systemic delivery of siRNA to target tissues is difficult to achieve owing to its limited cellular uptake and poor serum stability. Herein, polymeric nanoparticles were developed for systemic administration of siRNA to inflamed tissues. The polymeric nanoparticles were composed of PK3 as a pH-sensitive polymer, folate-polyethyleneglycol-poly(lactide-co-glycolide) as a targeting ligand, and a DOTAP/siRNA core. The polymeric nanoparticles had a mean particle size of 142.6 ± 0.61 nm and a zeta potential of 3.6 ± 0.43 mV. In vitro studies indicated pH-dependent siRNA release from polymeric nanoparticles, with accelerated release at pH 5.0. Cellular uptake was efficient and gene silencing was confirmed by Western blot. In vivo, polymeric nanoparticles were shown to have inflammation-targeting activity and potent therapeutic effects in an adjuvant-induced arthritis rat model. These results suggest that pH-sensitive and folate receptor-targeted nanoparticles are a promising drug carrier for siRNA delivery for rheumatoid arthritis.
[Bone metabolism during pregnancy and breast feeding. Osteoporosis in pregnancy].

M. Audran

Abstract:
A biomimetic adipocyte mesenchymal stem cell membrane-encapsulated drug delivery system for the treatment of rheumatoid arthritis

Chaoyu Gu,Shaoying Yang,Xuesong Liu,Yi Jin,Ye Yu,Liangjing Lu

DOI: https://doi.org/10.1007/s12274-023-5877-6

IF: 9.9

2023-07-05

Nano Research

Abstract:Rheumatoid arthritis (RA) is a chronic, progressive, and inflammatory systemic autoimmune disease. Effective drug therapy for RA is hindered by severe side effects due to inefficient delivery to the disease site and broad drug distribution. Inspired by biomimetic biology, this study developed a drug delivery system of adipose-derived mesenchymal stem cell membrane-encapsulated nanoparticles for the treatment of RA. The intact adipose-derived mesenchymal stem cell (ADSC) membrane was coated on poly (lactic-co-glycolic acid) (PLGA) nanoparticles and loaded with tacrolimus (FK506), a T cell inhibitor. The ADSC membrane encapsulated on nanoparticles retains the original homing properties of ADSC, targeting the inflamed joints and enhancing tacrolimus anti-inflammatory effect. Both in vitro and in vivo experiments proved that the synergistic effect of the ADSC-membrane and tacrolimus effectively inhibited inflammation in vivo and reduced the expression of pro-inflammatory factors (IL-1 β , IL-6, tumor necrosis factor- α (TNF- α )), and increased the expression of anti-inflammatory factors (IL-10). In addition, collagen-induced arthritis (CIA) model results also showed that the drug delivery system could effectively reduce the destruction of articular cartilage and bone in mice without causing any adverse effects. This study provided a new biomimetic targeting strategy to reshape the inflammatory microenvironment by modulating T cell subsets, providing new inspiration for RA treatment.

materials science, multidisciplinary,chemistry, physical,physics, applied,nanoscience & nanotechnology
Dual-Drug Loaded Separable Microneedles for Efficient Rheumatoid Arthritis Therapy

Mengchen An,Mengxiao Shi,Jingjing Su,Yueru Wei,Rongrong Luo,Pengchao Sun,Yongxing Zhao

DOI: https://doi.org/10.3390/pharmaceutics14071518

IF: 6.525

2022-07-22

Pharmaceutics

Abstract:Although the inhibitors of the interleukin-6 receptor (IL-6R) and tumor necrosis factor-α (TNF-α) have achieved a certain success in the clinical treatment of rheumatoid arthritis (RA), great effort should be made to overcome side effects and to improve patient compliance. The present research aimed to address these problems by the co-delivery of tocilizumab (TCZ)—an inhibitor of IL-6R—and an aptamer Apt1-67, which specifically inhibits TNF receptor 1 via separable microneedles (MN). MN were featured with a sustained release of TCZ from needle tips and a rapid release of Apt1-67 from needle bodies by using methacrylate groups grafted hyaluronic acid as the fillings of needle tips and polyvinyl alcohol/polyvinyl pyrrolidone as the fillings of needle bodies. Our results demonstrated that TCZ and Apt1-67 were distributed in MN as expected, and they could be released to the surroundings in the skin. In vivo studies revealed that combined medication via MN (TCZ/Apt1-67@MN) was superior to MN loaded with a single drug. Compared with subcutaneous injection, TCZ/Apt1-67@MN was of great advantage in inhibiting bone erosion and alleviating symptoms of CIA mice. This study not only provides a novel approach for combined medication with different release properties but also supplies a strategy for improving drug efficacy.

pharmacology & pharmacy
Cyclical changes in and significance of lipids and acid phosphatase activity in the seminiferous tubules of the rat testis

M. Niemi,M. Kormano

DOI: https://doi.org/10.1002/ar.1091510207

1965-02-01

The Anatomical Record

Abstract:The distribution of tubular lipids and acid phosphatase activity was studied in the rat testis and in the ductuli efferentes. The results were referred to the stage of the cycle of the seminiferous epithelium. The significance of the lipids and phosphatase of the ducts was tested in animals, where excretory ducts were separated from testis for 30 to 40 days.

Recognizing heart disease. Helping women seek treatment faster.

Frequency and causes of premature extractions of deciduous molar teeth – a retrospective study

Developing an Evaluation Plan for Nationwide Data Infrastructure Programs

Macrophage membrane-camouflaged biomimetic nanoparticles for rheumatoid arthritis treatment via modulating macrophage polarization

Efficient Treatment of Rheumatoid Arthritis by Degradable LPCE Nano-Conjugate-Delivered p65 siRNA

Biomimetic chitosan nanoparticles with simultaneous water lubricant and anti-inflammatory

Targeted co-delivery biomimetic nanoparticles reverse macrophage polarization for enhanced rheumatoid arthritis therapy

Nanoparticle-delivered siRNA targeting Bruton's tyrosine kinase for rheumatoid arthritis therapy

Radicals Scavenging MOFs Enabling Targeting Delivery of siRNA for Rheumatoid Arthritis Therapy

CaP-based anti-inflammatory HIF-1α siRNA-encapsulating nanoparticle for rheumatoid arthritis therapy

Biomimetic Hybrid Membrane-Coated Xuetongsu Assisted with Laser Irradiation for Efficient Rheumatoid Arthritis Therapy

[Primacy of immunologic derangement over the immunopathologic changes and hemodynamic disorders in Hansenian neuritis].

Notch-1 siRNA and Methotrexate towards a Multifunctional Approach in Rhematoid Arthritis Management: a Nanomedicine Approach

Biomimetic nanoparticles with cell-membrane camouflage for rheumatoid arthritis

A novel indomethacin/methotrexate/MMP-9 siRNA in situ hydrogel with dual effects of anti-inflammatory activity and reversal of cartilage disruption for the synergistic treatment of rheumatoid arthritis

DEMONSTRATION OF SEPARATE RECEPTORS FOR HUMAN IgA AND IgG IN GROUP A STREPTOCOCCI TYPE

Delivery of siRNA using folate receptor-targeted pH-sensitive polymeric nanoparticles for rheumatoid arthritis therapy

[Bone metabolism during pregnancy and breast feeding. Osteoporosis in pregnancy].

A biomimetic adipocyte mesenchymal stem cell membrane-encapsulated drug delivery system for the treatment of rheumatoid arthritis

Dual-Drug Loaded Separable Microneedles for Efficient Rheumatoid Arthritis Therapy

Cyclical changes in and significance of lipids and acid phosphatase activity in the seminiferous tubules of the rat testis